
NewCaff™ Micro-encapsulated caffeine for controlled release and a clean taste
NewCaff™ is a new source of microencapsulated caffeine :
– provides for a sustained release of caffeine, prolonging caffeine’s stimulating effect without the caffeine crash ;
– masks the bitter taste of caffeine.
EFSA has published five positive opinions on caffeine. It increases alertness, attention and endurance capacity.
NewCaff™ is available in France and Benelux.
Description
Composition and characteristics
Caffeine, an alkaloid of the methylxanthine class, is also known as 1,3,7-trimethylxanthine.
Caffeine is a chemical compound that has natural and synthetic sources. Natural sources of caffeine are mainly derived from various plant families native to South America such as coffee and cocoa beans, tea leaves, and guarana berries.
NewCaff™ is available in two concentrations: 60% or 75% caffeine.
Observations using scanning electron microscopy show that caffeine has an angular, polyhedral shape (a), whereas microcapsules containing caffeine are round shaped (b).
(a) Before micro-encapsulation

(b) After micro-encapsulation (NewCaff™-60).

Spectroscopy (DLS) has shown that microcapsules measure from 400 to 680 µm in diameter.
Regulatory Information
In the EU, caffeine is considered a traditional ingredient and does not fall under Novel Food regulations.
Caffeine is authorized in food supplements according to French Decree No. 2006-352 of 20 March 2006.
It has GRAS status (No. 347 in the FDA database).
Following a request from the European Commission, EFSA issued a scientific opinion on the safety of caffeine in 2015 (question EFSA No. EFSA-Q-2013-00220).

This scientific opinion of EFSA on caffeine (2015) concludes that consumption of 400 mg of caffeine per day with single doses of up to 200 mg (3 mg/kg body weight (bw) for an adult weighing 70 kg) does not pose any safety concerns for healthy adults (except for pregnant women).
The FDA also concluded that consumption of more than 400 mg of caffeine per day for adults in good health is not associated with harmful or dangerous effects.
Sources:
– EFSA, 2015. Scientific Opinion on the safety of caffeine Tabs. EFSA Journal 2015; 13(5):4102 [120 pp.].
– Lipofoods. NewCaff Global presentation, 2016.
– Synadiet, Ingredient fact sheet: La caféine, 2012.
Technological Properties and Formulation
Micro-encapsulation of caffeine is carried out on a fluidized bed composed of high melting point lipids. The caffeine particles are coated with a mixture of solid and liquid lipids that are sprayed on through a nozzle.
Each particle is uniformly coated to form a smooth coating:

source: Glat GmbH.
This technique ensures the slow release of caffeine and completely masks the bitter taste.
Sensory evaluation using a triangle test has shown that NewCaff™ successfully masks the bitter taste of caffeine.
NewCaff™ can be used in a large range of food products and food supplements: energy powders, bars, gels, chewing gum, confectionery, etc.
Sources:
- Lipofoods. NewCaff Global presentation, 2016.
Nutrition and Health Claims
Five health claims for caffeine have been reviewed and approved by EFSA.
The European Commission published a draft regulation to authorize four health claims for which EFSA concluded that there are no adverse health effects in May 2015. In application of Article 88-4 of the French Constitution regarding EU draft regulations, the text was also submitted to the French National Assembly and Senate.
– Caffeine helps to increase alertness (EFSA, ID 736, 1011, 1187, 1485, 1491, 2063, 2103) *
– Caffeine helps to increase attention (EFSA, ID 736, 1485, 1491, 2375) *
– Caffeine helps to increase endurance performance (EFSA, ID 737, 1486) **
– Caffeine helps to increase endurance capacity** (EFSA, ID 1488)
* The claim cannot be used for food targeting children, including adolescents The claim is authorized for doses of a minimum of 75 mg of caffeine per intake.
** The claim can only be used for food that exclusively targets adults performing endurance exercise. The claim is authorized at doses of 3 mg/kg bw.
These four claims can be used if the consumer is warned not to exceed the recommended daily dose of 400 mg of caffeine, regardless of its source (200 mg for pregnant or breastfeeding women).
The European Commission (EC) rejected the fifth health claim stipulating that caffeine “reduces the rated perceived effort during exercise” for which EFSA concluded that there were no adverse effects [for adults performing endurance exercise] (at doses of 4 mg/kg bw).
In June 2016, the members of the EU Committee on the Environment, Public Health and Food Safety (ENVI) opposed the draft regulation. In their resolution, the MEPs point out that the EC itself considers that claims that caffeine helps to increase alertness and concentration should not be used for foods targeting children and adolescents. However, adolescents are the largest group of consumers of energy drinks, which also contain high amounts of sugar (Press release, European Parliament, 15 June 2016).
The ENVI Committee members approved the resolution to veto the claim by a show of hands, calling for Parliament to vote against the draft regulation during the July plenary session in Strasburg.

The European parliament finally calls on the Commission to withdraw the draft regulation on July 7th 2016. (European Parliament resolution of 7 July 2016)
Sources:
- European Commission. COMMISSION IMPLEMENTING REGULATION (EU) 2016/854 of 30 May 2016 authorising certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health and amending Regulation (EU) No 432/2012.